Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 1, 2024
Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T Builds on long-standing relationship between the two companies In